AU2020319164A1 - Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment - Google Patents

Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment Download PDF

Info

Publication number
AU2020319164A1
AU2020319164A1 AU2020319164A AU2020319164A AU2020319164A1 AU 2020319164 A1 AU2020319164 A1 AU 2020319164A1 AU 2020319164 A AU2020319164 A AU 2020319164A AU 2020319164 A AU2020319164 A AU 2020319164A AU 2020319164 A1 AU2020319164 A1 AU 2020319164A1
Authority
AU
Australia
Prior art keywords
sotagliflozin
patients
dose
type
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020319164A
Other languages
English (en)
Inventor
David Bregman
Ali Hariri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lexicon Pharmaceuticals Inc
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AU2020319164A1 publication Critical patent/AU2020319164A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020319164A 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment Abandoned AU2020319164A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188477.4A EP3769767A1 (en) 2019-07-25 2019-07-25 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
EP19188477.4 2019-07-25
PCT/IB2020/057016 WO2021014420A1 (en) 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment

Publications (1)

Publication Number Publication Date
AU2020319164A1 true AU2020319164A1 (en) 2022-02-24

Family

ID=67438963

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020319164A Abandoned AU2020319164A1 (en) 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment

Country Status (7)

Country Link
US (1) US20220265690A1 (cg-RX-API-DMAC7.html)
EP (2) EP3769767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541322A (cg-RX-API-DMAC7.html)
CN (1) CN114222571A (cg-RX-API-DMAC7.html)
AU (1) AU2020319164A1 (cg-RX-API-DMAC7.html)
CA (1) CA3148400A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014420A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010959A2 (en) 2006-07-14 2008-01-24 The Trustees Of The University Of Pennsylvania Beam ablation lithography

Also Published As

Publication number Publication date
CA3148400A1 (en) 2021-01-28
CN114222571A (zh) 2022-03-22
WO2021014420A1 (en) 2021-01-28
EP4003366A1 (en) 2022-06-01
US20220265690A1 (en) 2022-08-25
JP2022541322A (ja) 2022-09-22
EP3769767A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
US20240115708A1 (en) Dosing Regimens For The Treatment Of Fabry Disease
Danne et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study
Cherney et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Allegaert et al. Developmental pharmacokinetics in neonates: maturational changes and beyond
AU2012328388A1 (en) Treatment protocol of diabetes type 2
Zakaraia et al. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial.
Sosale et al. A prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: real world evidence from clinical practice in India
EP4003366A1 (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
Powell et al. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management
Karyekar et al. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes
Bellomo Damato et al. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
HK40062957A (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
JP7482146B2 (ja) 1型真性糖尿病を有する患者の治療のためのソタグリフロジンの使用
US20130072454A1 (en) Anti-diabetic compostions and methods
Sharma Section 8: Diabetes Care in Special Populations
Gupta 25 Intensive Glycemic Control: Is it
Bermejo et al. 4CPS-070 Study of cardiovascular toxicity associated with ibrutinib treatment
Hwang et al. Dose-dependent glucosuria of DWP16001, a novel selective SGLT-2 inhibitor, in healthy subjects
Mohamad Hosein Zade Davatgari et al. Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient Treated with Empagliflozin: Case Report
Hosein et al. Canagliflozin: A First-in-Class Medication for the Treatment of Type 2 Diabetes Mellitus
HK40036814A (en) Dosing regimens for the treatment of fabry disease
de Souza Faustino et al. The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
NZ615726B2 (en) Dosing regimens for the treatment of fabry disease
NZ715144A (en) Insulin glargine/lixisenatide fixed ratio formulation
EP4051281A1 (en) Treatment of diabetic nephropathy with an sgc stimulator

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period